Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS)

BACKGROUND: Roxadustat is an orally active hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of chronic kidney disease (CKD) anemia. METHODS: This Phase 3, multicenter, randomized, double-blind, placebo-controlled study examined patients with Stages 3–5 CKD, not on dialysis (NC...

Descripción completa

Detalles Bibliográficos
Autores principales: Shutov, Evgeny, Sułowicz, Władysław, Esposito, Ciro, Tataradze, Avtandil, Andric, Branislav, Reusch, Michael, Valluri, Udaya, Dimkovic, Nada
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397511/
https://www.ncbi.nlm.nih.gov/pubmed/33630072
http://dx.doi.org/10.1093/ndt/gfab057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397511/
https://www.ncbi.nlm.nih.gov/pubmed/33630072
http://dx.doi.org/10.1093/ndt/gfab057

Ejemplares similares